cis-Dichlorodiammineplatinum(II) for the treatment of advanced ovarian cancer.

摘要: cis-Dichlorodiammineplatinum(II) (cis-platinum) was used in the treatment of 25 patients with advanced ovarian adenocarcinoma refractory to alkylating agents. Seven 24 evaluable (29%) responded cis-platinum (one complete response and six partial responses). Life-table analysis survival indicates that responding therapy survive longer than those who fail respond (9 months versus 3.2 months) (P = 0.014). In previously treated given 70 mg/m2 iv forced diuresis, there substantial nausea vomiting (100%), hematologic toxicity (67%), renal (34%). A review single-agent activity other cancer studies an overall rate 25% (40 161 patients). At least nine combination chemotherapy utilizing are progress, preliminary information from several these is encouraging suggests cis-platinum-containing combinations may have a major role adenocarcinoma.